Ubrogepant taken in the prodrome phase of migraine was superior to placebo in staving off an acute episode, and in facilitating continued functioning with less limitation on activity over 24 hours after the dose, according to an analysis from the PRODROME trial.
“Improving care at the first signs of migraine, even before headache pain begins, can be key to improved outcomes,” study lead author Richard Lipton, MD, of Albert Einstein College of Medicine in New York City, indicated in a